Aldeyra Therapeutics announced its financial and operating results for the third quarter and nine months ended September 30, 2015.
Article continues below
Net loss attributable to common stockholders of approximately $3.4 million compared to a net loss of approximately $2 million for the third quarter of 2014.
Basic and diluted net loss per share was $0.35 for the three months ended September 30, 2015 compared to basic and diluted net loss per share of $0.36 for the same period in 2014.
For the nine months ended September 30, 2015, Aldeyra reported a net loss attributable to common stockholders of approximately $7.7 million compared to a net loss attributable to common stockholders of approximately $7.1 million for the nine months ended September 30, 2014.
Basic and diluted net loss per share was $0.94 for the nine months ended September 30, 2015, compared to basic net loss per share of $2.21 and diluted net loss per share of $2.89 for the same period in 2014.
Research and development expenses totaled approximately $2.1 million for the third quarter of 2015 compared to approximately $1.2 million for the third quarter of 2014. For the nine months ended September 30, 2015, research and development expenses totaled approximately $4.5 million compared to $2.3 million for the nine months ended September 30, 2014.
For the third quarter of 2015, general and administrative expenses were approximately $1.3 million compared to approximately $800,000 for the third quarter of 2014.
For the nine months ended September 30, 2015, general and administrative expenses totaled approximately $3.2 million compared to $2.6 million for the nine months ended September 30, 2014.
Total operating expenses for the third quarter of 2015 were approximately $3.3 million compared to total operating expenses of approximately $2.0 million for the third quarter of 2014. For the nine months ended September 30, 2015, total operating expenses totaled approximately $7.7 million compared to $4.9 million for the nine months ended September 30, 2014.
As of September 30, 2015, Aldeyra had cash and cash equivalents of $30.6 million. ■